OrbiMed's continued large-scale selling, now $46.3M in a single notice plus $48.9M in recent sales, signals potential overhang and lack of insider conviction. Despite strong analyst sentiment, the persistent insider distribution warrants caution. Monitor for actual execution and any further 144 filings.
SION drugs
SION drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $40.90entry
- T+1 · 6mo ago −10.81%α −10.95% · $36.48
- T+5 · 5mo ago −13.52%α −10.77% · $35.37
- T+20 · 5mo ago +7.55%α +8.85% · $43.99
- T+60 · 3mo ago −84.72%α −85.95% · $6.25
Price Chart
How similar events traded
Executive Summary
OrbiMed Advisors LLC filed a Form 144 on May 29, 2026, signaling intent to sell 1,082,480 shares of Sionna Therapeutics common stock, valued at approximately $46.3 million. This represents a large-scale sell by a major pre-IPO investor, following a series of recent sales by the same entity totaling over $39 million in April–May 2026.
Key Facts
- OrbiMed Advisors LLC (via OrbiMed Private Investments VIII, LP) filed Form 144 to sell 1,082,480 shares of SION common stock.
- Estimated aggregate value of proposed sale: approximately $46.3 million.
- Shares were acquired on 02/10/2025 in the IPO for cash.
- OrbiMed has sold 1,082,480 shares in the past 3 months (since 04/14/2026) totaling ~$48.9 million.
- Recent insider selling (30d) totals $26.7M across 6 transactions, all by OrbiMed.
- Market cap is $1.9B; proposed sale represents ~2.4% of market cap.
- Sionna has 88% analyst bullish consensus (6 Strong Buy, 8 Buy).
Financial Impact
Proposed sale of 1,082,480 shares valued at ~$46.3M, representing ~2.4% of SION's $1.9B market cap.
Risk Factors
- Continued insider selling pressure from a major pre-IPO holder.
- Potential negative signal about near-term prospects or valuation.
- Possible further dilution if OrbiMed continues to reduce its position.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000947871-26-000586 |
| Document: 0000947871-26-000586-index.html | 0000947871-26-000586 |
| Document: 0000947871-26-000586.txt | 0000947871-26-000586 |
Track record
22 reports on SION
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers